Platelet rich plasma treatment arm for Azoospermia

Phase-Based Progress Estimates
Stanford Urology Clinic, Stanford, CA
Azoospermia+4 More
Platelet rich plasma - Biological
What conditions do you have?

Study Summary

Investigate the effect of intratesticular injection of autologous platelet rich plasma (PRP) on sperm retrieval rates and IVF outcomes in infertile men who already underwent a negative sperm retrieval. Currently, there is no alternative treatment after failed TESE. Prior series suggest that intratesticular PRP injections may improve TESE outcomes. We hope to determine whether PRP is an effective treatment for this patient population.

Eligible Conditions

  • Nonobstructive Azoospermia
  • Azoospermia
  • Men Infertility

Treatment Effectiveness

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 3 months after PRP injection

Month 3
sperm present

Trial Safety

Trial Design

1 Treatment Group

Platelet rich plasma treatment arm
1 of 1
Experimental Treatment

10 Total Participants · 1 Treatment Group

Primary Treatment: Platelet rich plasma treatment arm · No Placebo Group · N/A

Platelet rich plasma treatment arm
Experimental Group · 1 Intervention: Platelet rich plasma · Intervention Types: Biological
First Studied
Drug Approval Stage
How many patients have taken this drug
Platelet rich plasma
Completed Phase 4

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 3 months after prp injection

Trial Background

Michael Eisenberg, Principal Investigator
Principal Investigator
Stanford University
Closest Location: Stanford Urology Clinic · Stanford, CA
N/AFirst Recorded Clinical Trial
1 TrialsResearching Azoospermia
0 CompletedClinical Trials

Eligibility Criteria

Age 18+ · Male Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.